Stockreport

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc.  (DYN) 
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm Check Earnings Report
US:NYSE Investor Relations: dynegy.com/investors/presentations-events
PDF - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrationa [Read more]